前列腺癌中的循环素依赖性激酶抑制:过去,现在和未来
Matthew Siskin1, Minas P Economides1, David R Wise1
1Genitourinary Medical Oncology Service, Perlmutter Cancer Center, NYU Langone Heath Center, New York, NY 10016, USA.
Cancers
|March 13, 2025
概括
循环素依赖激酶 (CDK) 4/6 抑制剂在前列腺癌中表现有前途,但早期结果令人失望. 目前正在进行研究,以克服耐药性并确定患者子集,这些细胞循环向药物将使患者受益最多.
科学领域:
- 在瘤学瘤学.
- 癌症治疗方法 癌症治疗方法
- 前列腺癌研究 研究前列腺癌
背景情况:
- 尽管治疗方面取得了进展,前列腺癌仍是导致死亡的重要原因.
- 在乳腺癌中成功的循环素依赖激酶 (CDK) 4/6 抑制剂正在为前列腺癌进行研究.
- 前列腺癌中CDK4/6抑制剂的初步临床试验结果在很大程度上令人失望.
研究的目的:
- 审查在前列腺癌中使用CDK4/6抑制剂的生物学理由.
- 要总结现有的临床数据和正在进行的试验的前列腺癌中CDK4/6抑制剂.
- 探索前列腺癌患者的抵抗机制和克服它们的策略.
主要方法:
- 对前列腺癌中CDK4/6抑制剂的生物学理由的审查.
- 对前列腺癌中CDK4/6抑制剂的现有临床数据的分析.
- 检查正在进行的临床试验和耐药性机制.
主要成果:
- 最初的研究发表的有限结果在很大程度上令人失望.
- 了解耐药机制对于有效治疗至关重要.
- 正在开发新的战略来克服阻力.
结论:
- 目前正在进行的试验旨在完善CDK4/6抑制剂在前列腺癌中的作用.
- 针对其他细胞循环蛋白 (例如CDK2,CDK7) 的新抑制剂的开发正在进行中.
- 组合疗法和基因组亚型化是确定可能受益于细胞循环向药物的患者亚组的关键.
相关概念视频
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
02:39Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
00:50Anaphase Promoting Complex
2.8K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.8K
01:23Negative Regulator Molecules
35.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K